# Study Evaluating Prevenar Immunogenicity in High Risk Children

> **NCT00581620** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 160 (actual)

## Conditions studied

- Vaccines, Pneumococcal Conjugate Vaccine

## Interventions

- **BIOLOGICAL:** pneumococcus conjugate vaccine

## Key facts

- **NCT ID:** NCT00581620
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2007-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00581620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00581620, "Study Evaluating Prevenar Immunogenicity in High Risk Children". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00581620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*